| Literature DB >> 30098712 |
Irvin M Modlin1, Mark Kidd2, Anna Malczewska3, Ignat Drozdov2, Lisa Bodei4, Somer Matar2, Kyung-Min Chung2.
Abstract
The neuroendocrine neoplasms test (NETest) is a multianalyte liquid biopsy that measures neuroendocrine tumor gene expression in blood. This unique signature precisely defines the biological activity of an individual tumor in real time. The assay meets the 3 critical requirements of an optimal biomarker: diagnostic accuracy, prognostic value, and predictive therapeutic assessment. NETest performance metrics are sensitivity and specificity and in head-to-head comparison are 4-fold to 10-fold more accurate than chromogranin A. NETest accurately identifies completeness of surgery and response to somatostatin analogs. Clinical registry data demonstrate significant clinical utility in watch/wait programs.Entities:
Keywords: Biomarker; Blood; Bronchopulomary carcinoid; Multigene blood analysis; NETest; Neuroendocrine tumors; PCR; Peptide receptor radionuclide therapy; Progression; Transcript
Mesh：
Substances：
Year: 2018 PMID： 30098712 PMCID： PMC6716518 DOI： 10.1016/j.ecl.2018.05.002
Source DB: PubMed Journal: Endocrinol Metab Clin North Am ISSN： 0889-8529 Impact factor: 4.741